May 10, 2019
The ADDF announces $7.1 million in new investments, which reflect our strategy to advance drug discovery and clinical trials, including the development of biomarkers and prevention methods.
June 20, 2018
Dr. Ron Crystal and his team at Weill Cornell developed a gene therapy to replace APOE4 with APOE2, which would significantly lower Alzheimer's risk.
September 24, 2014
Presenters at our recent conference shared exciting progress on new Alzheimer's drug targets and biomarkers.
August 18, 2014
New research reveals that a person without the APOE gene—which influences Alzheimer’s risk—can function normally, paving the way for gene therapies.